Key Highlights

  • BIO-key's second-quarter net loss narrowed 51% to $576,852 as gross Margin rose to 87% on a shift toward higher-margin software licensing, though Revenue growth of 13% fell short of management's earlier guidance.
  • The company won a national biometric authentication mandate from the Central Bank of Jordan and a Portuguese national security agency contract, though neither announcement disclosed a contract value.
  • Cash fell to $1.38 million from $2.7 million six months earlier, prompting an August Warrant inducement that raised roughly $2.5 million but added new warrants covering more shares than were then outstanding.

BIO-key International, Inc. (NASDAQ:BKYI) has spent 2026 doing two hard things at once: repairing its standing on the Nasdaq Capital Market after a listing scare, and chasing national-scale customers in banking, defence and government. On 13 August the Holmdel, New Jersey company put numbers to that effort, reporting second-quarter results with a much narrower loss but slower revenue growth than management had guided.

The report caps a dense six weeks. BIO-key has returned to Nasdaq trading, been selected by the Central Bank of Jordan for a national biometric authentication programme, won work with a Portuguese national security agency, and raised about $2.5 million by inducing an investor to exercise warrants.

The question hanging over Friday's 10am ET investor call is whether a pipeline that keeps producing headlines converts into recognised revenue fast enough to deliver the second-half profitability the company still says is achievable.

What Happened

BIO-key reported second-quarter revenue of $1.92 million, up 13% from $1.70 million a year earlier. Net loss narrowed 51% to $576,852, or $0.56 a share, from $1.17 million, or $2.01 a share. Per-share figures reflect the 1-for-10 Reverse Stock Split that took effect at the end of April.

The mix shifted decisively toward software. Licence fees jumped 53% to $1.23 million, while hardware revenue fell 19% to $459,641 and services slipped 28% to $231,005. Roughly $0.8 million of expected hardware revenue slid out of the quarter into the second half.

That matters, because in April and again in May BIO-key guided to first-half revenue of about $5 million and positive net income. Actual first-half revenue came in near $4.1 million, up 23% year on year, with a net loss of $781,889 - 59% smaller than a year earlier, but still a loss.

Why It Matters

BIO-key sells identity and access management software, the plumbing that decides who is allowed into a network, alongside fingerprint reader hardware. Its differentiator is what it calls Identity-Bound Biometrics: credentials tied to a person's fingerprint rather than to a phone, token or password, which it argues is far harder to phish, borrow or steal.

That argument is landing hardest outside the United States. On 28 July the Central Bank of Jordan said it had selected BIO-key's PortalGuard and WEB-key platforms for a national push to move the country's financial sector away from passwords and legacy tokens. On 10 August an unnamed Portuguese national security agency selected BIO-key and local partner Visualforma to secure critical systems using the same platforms plus the FBI-certified EcoID III fingerprint scanner.

Note what was not said: neither announcement disclosed a contract value, and the Jordanian central bank stated that scope and timeline are still being developed. These are selections, not yet quantified revenue.

The Numbers

Profitability metrics moved the right way. Gross Profit rose to $1.67 million from $1.23 million, lifting gross margin to 87% from 73% as higher-margin licences replaced hardware. Operating expenses edged down to $2.20 million from $2.32 million, extending cost discipline that cut 2025 operating expenses 7% to $9.0 million.

The Balance Sheet is thinner. Cash stood at $1.38 million at 30 June, down from $2.25 million at end-March and $2.7 million at 31 December 2025. Accounts Receivable were $1.73 million, current deferred revenue $653,529 and the note payable $699,769. Stockholders' Equity was $4.33 million across 1,087,360 shares.

For context, full-year 2025 revenue fell 12% to $6.1 million with a $4.6 million net loss. First-quarter 2026 revenue then rose 34% to $2.15 million and cut the quarterly loss to $165,000, helped by a $1.04 million licence renewal from a foreign retail bank with over 30 million enrolled clients.

What It Means for the Company

The revenue mix is arguably more encouraging than the headline growth rate. Licence revenue is recurring, carries very high incremental margin and grew 53%; hardware is lumpy, lower margin and the line that dragged. If the delayed $0.8 million of hardware lands in the second half as guided, it arrives on top of an expanding licence base.

BIO-key is also building distribution rather than selling everything directly, adding a US public-sector agreement with TD SYNNEX Public Sector (DLT) in March and a Saudi, Jordanian and UAE education alliance with Maktabi Tech on 6 August. Still, the maths is demanding: at an 87% gross margin the company needs quarterly revenue near $2.5 million to cover its $2.2 million expense base, leaving little room for further slips.

Risks Investors Should Watch

Funding is the most immediate issue. Cash roughly halved over six months, and on 11 August the company entered a warrant inducement in which an investor agreed to exercise 618,334 warrants at $4.06 for about $2.5 million in gross proceeds before fees, with Maxim Group LLC as exclusive Placement agent. In exchange the investor receives new five-year warrants over 1,236,668 shares at $4.06.

That is a meaningful dilution overhang: the new warrants alone cover more shares than the 1,087,360 outstanding at 30 June, and they become exercisable only if stockholders approve. A similar $3.1 million inducement closed in October 2025, making this a recurring funding pattern.

Listing risk has not fully cleared. BIO-key received Nasdaq non-compliance notices in April and June 2026 over late Form 10-K and Form 10-Q filings, executed the reverse split to address the minimum bid price rule, and only resumed Nasdaq trading on 8 July. It remains under a Discretionary Panel Monitor through 6 July 2027. Management also forecast first-half profitability and missed, and competes against far larger identity vendors.

What Comes Next

The nearest catalyst is the 14 August investor call with chairman and chief executive Mike DePasquale and chief financial officer Cecilia Welch, where the second-half profitability target and the timing of the deferred hardware revenue should be tested.

After that, watch the stockholder vote needed to make the new warrants exercisable, the resale registration statement, and any disclosure putting a dollar figure on the Jordan and Portugal engagements. Third-quarter results would normally follow in November.

Conclusion

BIO-key's operating trajectory is genuinely improving, gross margin expansion from the shift to software licensing is real and structural, not a one-quarter accounting effect, and the Jordan and Portugal wins show the Identity-Bound Biometrics pitch is landing with serious institutional buyers. What hasn't happened yet is conversion: neither deal comes with a disclosed contract value, first-half revenue missed the company's own guidance, and cash roughly halved in six months. The August 14 investor call, and whether the delayed $0.8 million of hardware revenue actually lands in the second half, will show whether BIO-key's second-half profitability target is achievable or another guidance miss in the making.